JAK1 and melanoma: Surprisingly, IFNγR1KO melanomas harbor an aberrantly active mTOR-JAK1/2 axis, which, when targeted with an FDA-approved JAK1/2 inhibitor Ruxo, results in potent and selective suppression of IFNγR1KO but not scrambled control melanomas, in a T cell and host TNF-dependent fashion.